Potential effect of angiotensin II receptor blockade in adipose tissue and bone

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3049-3053

  Nakagami, Hironori ^a   Osako, Mariana Kiomy ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Adipose tissue; Angiotensin II; Obesity; Osteoclast; Osteoporosis

Indexed keywords

ADIPOCYTOKINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CYTOKINE; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; VALSARTAN;

ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BONE METABOLISM; CELL ACTIVATION; CELL DIFFERENTIATION; DIET; DISEASE ASSOCIATION; DRUG EFFECT; ENERGY EXPENDITURE; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER FIBROSIS; LIVER PROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION; WEIGHT GAIN;

ADIPOSE TISSUE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BONE AND BONES; BONE DENSITY; HUMANS; OSTEOPOROSIS; PPAR GAMMA; RENIN-ANGIOTENSIN SYSTEM;

EID: 84878659233     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170011     Document Type: Article

References (41)

1. Rahmouni K, Mark AL, Haynes WG, et al. Adipose depot-specific modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol Endocrinol Metab 2004; 286: E891-5.
2. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15: 381-8.
3. Zorad S, Fickova M, Zelezna B, et al. The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Gen Physiol Biophys 1995; 14: 383-91.
4. Janke J, Engeli S, Gorzelniak K, et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-707.
5. Sharma AM, Janke J, Gorzelniak K, et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension, 2002; 40: 609-11.
6. Yamamoto R, Akazawa H, Fujihara H, et al. Angiotensin II type 1 receptor signaling regulates feeding behavior through anorexigenic corticotropin-releasing hormone in hypothalamus. J Biol Chem 2011; 286: 21458-65.
7. Kouyama R, Suganami T, Nishida J, et al. Attenuation of dietinduced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005; 146: 3481-9.
8. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacological reviews 2000; 52: 415-72.
9. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
10. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-7.
11. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270; 12953-6.
12. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
13. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002; 22: 167-97.
14. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-52.
15. Nakagami H, Osako MK, Takami Y, et al. Differential response of vascular hepatocyte growth factor concentration and lipid accumulation between telmisartan and losartan in ApoE-deficient mice. Mol Med Report. 2008; 1: 657-61.
16. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
17. Angulo, P. Obesity and nonalcoholic fatty liver disease. Nutr rev 2007; 65: S57-63.
18. Fujita K, Yoneda M, Wada K, et al. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci 2007; 52: 3455-64.
19. Sugimoto K, Qi NR, Kazdova L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003-9.
20. Nakagami H, Osako KM, Nakagami F, et al. Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. Int J Mol Med 2010; 26: 477-81.
21. Jin H, Yamamoto N, Uchida K, et al. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2007; 364: 801-7.
22. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet. 1999; 354: 971-5.
23. Mancini M, Ferrara AL, Strazzullo P, Marotta T. Metabolic disturbances and antihypertensive therapy. J Hypertens Suppl. 1991; 9: S47-50.
24. MacGregor GA, Cappuccio FP. The kidney and essential hypertension: a link to osteoporosis? J Hypertens. 1993; 11: 781-5.
25. McCarron DA, Pingree PA, Rubin RJ, et al. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension. 1980; 2: 162-8.
26. Young EW, McCarron DA, Morris CD. Calcium regulating hormones in essential hypertension. Importance of gender. Am J Hypertens. 1990; 3: 161S-166S.
27. Ma YF, Stimpel M, Liang H, et al. Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol. 1997;154: 467-74.
28. Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med. 2003; 16: 476-82.
29. Wasnich R, Davis J, Ross P, Vogel J. Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ. 1990; 301: 1303-5.
30. Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000; 109: 362-70.
31. LaCroix AZ, Ott SM, Ichikawa L, et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 133: 516-26.
32. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of betablockers and risk of fractures. JAMA. 2004; 292: 1326-32.
33. Hatton R, Stimpel M, Chambers TJ. Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 1992; 152: 5-10.
34. Hiruma Y, Inoue A, Hirose S, Hagiwara H. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun. 1997; 230: 176-8.
35. Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008; 22: 2465-75.
36. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
37. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-602.
38. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-23.
39. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000; 97: 1566-71.
40. Jimi E, Nakamura I, Duong LT, et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999; 247: 84-93.
41. van der Pluijm G, Most W, van der Wee-Pals L, et al. Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast development and subsequent resorption of mineralized matrix. Endocrinology 1991; 129: 1596-604.